HPV Independent Squamous Cell Carcinoma of the Oropharynx: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC
April 10, 2026

HPV-independent squamous cell carcinoma is a type of cancer that develops in the oropharynx — the part of the throat located behind the mouth — that is not caused by human papillomavirus (HPV). The oropharynx includes the tonsils, the base of tongue (the back one-third of the tongue), the soft palate, and the back wall of the throat.

The term “HPV-independent” is important because it distinguishes this cancer from HPV-associated squamous cell carcinoma, which is a different disease with a better prognosis. Both types arise from squamous cells in the same part of the throat, but they have different causes, microscopic appearances, staging systems, and outcomes. Understanding which type you have is essential because it directly shapes how the cancer is treated and what prognosis to expect.

This article will help you understand the findings in your pathology report — what each term means and why it matters for your care.

What causes HPV-independent squamous cell carcinoma?

HPV-independent squamous cell carcinoma of the oropharynx is caused by cumulative damage to the squamous cells lining the throat, most often from long-term tobacco and alcohol use. Tobacco — in any form — is the single most important risk factor, and the combination of heavy smoking and heavy alcohol use multiplies the risk substantially beyond either factor alone. The damage accumulates over many years, causing progressive genetic changes in the squamous cells that eventually lead to cancer. Unlike HPV-associated oropharyngeal cancer, which can arise in people without significant tobacco or alcohol history, this type of cancer is strongly linked to these modifiable lifestyle risk factors.

Other contributing factors include prior radiation to the head and neck region, chronic immune suppression (for example after organ transplantation), and, in rare cases, inherited conditions that impair DNA repair. Poor oral hygiene and chronic irritation may also play a role.

What are the symptoms?

HPV-independent squamous cell carcinoma of the oropharynx can cause a range of symptoms depending on the size and location of the tumor. Common symptoms include:

• A persistent sore throat that does not resolve with antibiotics
• Pain or difficulty swallowing
• Ear pain on one side (referred pain from the throat)
• A lump or thickening in the neck, which may represent cancer spread to a lymph node
• A visible or palpable mass on the tonsil or back of the tongue
• Voice changes or hoarseness
• Unexplained weight loss

Unlike HPV-associated oropharyngeal cancer — where the primary tumor is often very small and the main presenting sign is an enlarged neck lymph node — HPV-independent tumors are more often visible as a larger, keratinizing mass in the throat at the time of diagnosis.

How is the diagnosis made?

The diagnosis is made after a tissue sample is examined under the microscope by a pathologist. The sample is obtained by biopsy from the oropharynx — most often the tonsil or base of tongue — or from an enlarged lymph node in the neck. If a neck lymph node is first biopsied by fine-needle aspiration (FNA), a biopsy of the oropharynx is usually performed to confirm the primary site.

Under the microscope, HPV-independent squamous cell carcinoma typically has a keratinizing appearance — the cancer cells produce keratin, a tough protein normally made by squamous cells, which appears as pink whorls or pearls under the microscope. This keratinizing pattern is the most important microscopic feature distinguishing HPV-independent from HPV-associated oropharyngeal carcinoma, which is typically non-keratinizing. The pathologist also performs p16 immunohistochemistry testing (see below) to confirm the absence of HPV association. Once cancer is confirmed, imaging — typically a contrast-enhanced CT or MRI of the head and neck, and often a PET-CT — determines the extent of the tumor and identifies involved lymph nodes.

How is HPV status confirmed?

Determining whether a squamous cell carcinoma of the oropharynx is HPV-associated or HPV-independent is mandatory because it changes both the staging system used and the prognosis. Two main tests are used:

• p16 immunohistochemistry (IHC) — p16 is a protein that becomes strongly overproduced in cells driven by high-risk HPV. A positive result — defined as strong, diffuse staining in at least 70% of tumor cells — is used as a surrogate marker for HPV association. In HPV-independent squamous cell carcinoma, the p16 result is negative (absent or only focal/weak staining). Your report will state the p16 result explicitly.
• HPV in situ hybridization (ISH) or PCR — These tests directly detect HPV DNA or RNA in tumor cells. They are sometimes used to confirm the p16 result or when a keratinizing tumor shows unexpectedly strong p16 staining.

A diagnosis of HPV-independent squamous cell carcinoma requires both the presence of invasive squamous cell carcinoma under the microscope and a negative HPV test (typically negative p16 IHC). The staging system for this cancer — based on the traditional size-and-extension approach — is different from the node-count system used for HPV-associated disease.

Histologic grade

Unlike HPV-associated oropharyngeal carcinoma — which is not graded because its cells share a uniform non-keratinizing appearance — HPV-independent squamous cell carcinoma is assigned a histologic grade. Grade describes how closely the cancer cells resemble normal squamous cells and how much keratin they produce.

• Well differentiated — The cells closely resemble normal squamous cells and produce abundant keratin, sometimes forming round structures called keratin pearls. These tumors tend to grow more slowly.
• Moderately differentiated — The cells show greater variation in size and shape and produce less keratin. More likely to invade adjacent tissue than well-differentiated tumors.
• Poorly differentiated — The cells look very different from normal squamous cells and produce little or no keratin. These tumors tend to be more aggressive and spread more readily.

Your pathology report will state the histologic grade because it helps predict tumor behavior and guides treatment planning.

Tumor extension

Tumor extension describes how far the cancer has grown beyond its original site in the oropharynx. As the tumor grows, it can extend into adjacent structures such as the lateral or posterior pharyngeal wall, the parapharyngeal space, or the soft tissue of the neck. Large tumors may invade the oral cavity, the deep muscles of the tongue, the larynx (voice box), or the mandible (lower jaw). Extension into these structures raises the tumor to a higher stage (pT4) and typically requires more extensive surgery and adjuvant radiation or chemoradiation.

Perineural invasion

Perineural invasion means cancer cells are growing along or around a nerve. In the oropharynx, nerves carry sensation and movement signals to the throat and surrounding areas. When tumor cells travel along nerve pathways, the cancer is more likely to recur locally and may be harder to eradicate with surgery alone. Perineural invasion is a high-risk feature that frequently prompts a recommendation for radiation therapy after surgery, and it may influence the radiation field used. Your report will state whether perineural invasion is present or absent.

Lymphovascular invasion

Lymphovascular invasion means cancer cells have entered lymphatic channels or blood vessels near the tumor. These provide a route for cancer to spread to lymph nodes or, through the bloodstream, to distant organs. Your report will state whether lymphovascular invasion is present or absent. Its presence is considered an adverse feature and may influence treatment recommendations.

Surgical margins

Margins are the edges of tissue removed during surgery. The pathologist examines the cut surfaces to determine how close the tumor comes to each edge.

• Negative margin — No cancer cells at the cut edge. This suggests the tumor was completely removed.
• Close margin — Cancer cells are within a few millimeters of the edge. This is a concern and may prompt adjuvant radiation.
• Positive margin — Cancer cells are present at the cut edge. This indicates some tumor may remain and typically leads to a recommendation for further treatment — either re-excision or radiation.

Positive or close margins are a high-risk feature in HPV-independent oropharyngeal SCC and, together with other adverse pathologic findings, often lead to recommendations for combined chemoradiation after surgery.

Lymph nodes

Lymph nodes are small immune organs in the neck that can trap cancer cells spreading through the lymphatic system. The oropharynx drains to lymph nodes at levels II through IV on both sides of the neck. A neck dissection to remove these lymph nodes is usually performed as part of surgery for HPV-independent oropharyngeal SCC.

Your report will include the total number of lymph nodes examined, the number containing cancer, the size of the largest tumor deposit, and whether extranodal extension is present — meaning cancer cells have broken through the outer capsule of a lymph node into the surrounding tissue. Extranodal extension is a particularly important adverse finding in HPV-independent disease: it is one of the strongest predictors of recurrence and death, and its presence is a standard indication for adjuvant concurrent chemoradiation after surgery.

Lymph node involvement carries a more serious prognostic significance in HPV-independent oropharyngeal SCC than in the HPV-associated type. Both the number of involved nodes and their size contribute to the nodal stage (pN).

PD-L1

PD-L1 is a protein that some cancer cells produce to shield themselves from immune attack. Immunotherapy drugs called checkpoint inhibitors — particularly pembrolizumab (Keytruda) and nivolumab (Opdivo) — block this mechanism, allowing the immune system to recognize and attack the cancer.

PD-L1 testing is typically performed when the cancer is unresectable, has returned after treatment, or has spread to distant sites. Results are reported as a Combined Positive Score (CPS), measuring PD-L1 expression on both tumor cells and surrounding immune cells. A CPS of 1 or higher indicates that immunotherapy may provide benefit. Your oncologist will use the CPS result to determine whether immunotherapy should be part of your treatment plan.

Pathologic stage (pTNM)

HPV-independent squamous cell carcinoma of the oropharynx uses a traditional size-and-extension staging system — the same approach used for oral cavity squamous cell carcinoma. This differs importantly from the HPV-associated oropharyngeal staging system, which is based primarily on the number of lymph nodes rather than their size. The HPV-independent system assigns more weight to the number, size, and location of involved lymph nodes, reflecting the worse prognosis associated with nodal disease in HPV-negative patients.

Tumor stage (pT)

• pT1 — Tumor 20 mm or smaller in greatest dimension.
• pT2 — Tumor larger than 20 mm but 40 mm or smaller.
• pT3 — Tumor larger than 40 mm, or extension to the lingual surface of the epiglottis.
• pT4a — Tumor invades adjacent structures such as the larynx, deep extrinsic muscles of the tongue, medial pterygoid muscle, hard palate, or mandible.
• pT4b — Tumor invades the lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases the carotid artery. (Very advanced, typically not fully resectable.)

Nodal stage (pN)

• pN0 — No cancer in any lymph nodes examined.
• pN1 — Cancer in a single lymph node on the same side as the tumor, 30 mm or smaller, with no extranodal extension.
• pN2a — Cancer in a single lymph node on the same side, larger than 30 mm but not more than 60 mm, with no extranodal extension.
• pN2b — Cancer in multiple lymph nodes on the same side, all 60 mm or smaller, with no extranodal extension.
• pN2c — Cancer in lymph nodes on both sides of the neck, all 60 mm or smaller, with no extranodal extension.
• pN3a — Cancer in a lymph node larger than 60 mm.
• pN3b — Extranodal extension present in any involved lymph node.

What is the prognosis for HPV-independent squamous cell carcinoma?

The prognosis for HPV-independent squamous cell carcinoma of the oropharynx is significantly worse than for HPV-associated oropharyngeal cancer at comparable stages. This difference is fundamental to understanding this diagnosis: the same number of involved lymph nodes, or the same tumor size, carries a much greater risk of recurrence and death in HPV-independent disease than in HPV-associated disease, which is why the two cancers use separate staging systems.

Five-year survival rates for HPV-independent oropharyngeal SCC are substantially lower — typically in the range of 30–50% for locally advanced disease — compared to the 70–85% commonly reported for HPV-associated disease of similar stage. Even early-stage HPV-independent tumors carry a higher recurrence risk than their HPV-associated counterparts.

The pathologic features that most strongly predict worse outcomes in HPV-independent disease are:

• Extranodal extension — The single strongest pathologic predictor of recurrence and reduced survival. It routinely prompts recommendations for concurrent chemoradiation after surgery.
• Positive or close surgical margins — Associated with high rates of local recurrence.
• Perineural invasion — Increases risk of local failure and may require expanded radiation fields.
• Higher tumor stage (pT3–T4) — Reflects deep tissue invasion or extension into adjacent structures.
• Multiple involved lymph nodes or large nodal deposits — Each additional positive node increases recurrence risk.
• Poorly differentiated grade — Associated with more aggressive behavior and faster growth.
• Continued tobacco use after treatment — Significantly worsens outcomes and increases the risk of a second primary cancer in the head and neck or lungs.

Stopping tobacco and alcohol use before, during, and after treatment is one of the most important steps a patient can take to improve their prognosis and reduce the risk of recurrence.

What happens after the diagnosis?

After diagnosis, your healthcare team reviews your pathology report, imaging studies, and overall health to develop a treatment plan. The team typically includes a head and neck surgeon, a radiation oncologist, a medical oncologist, and a pathologist.

For most patients with HPV-independent oropharyngeal SCC, treatment is more intensive than for HPV-associated disease, reflecting the worse prognosis. Surgery with neck dissection is often the primary treatment for resectable tumors. For tumors with high-risk pathologic features — positive or close margins, perineural invasion, extranodal extension, or multiple involved lymph nodes — adjuvant concurrent chemoradiation (radiation combined with chemotherapy to sensitize the cancer cells) is typically recommended after surgery. For some patients, definitive chemoradiation without surgery may be the preferred approach, particularly for large tumors or those involving critical structures.

For recurrent or metastatic disease, treatment options include chemotherapy, targeted therapy with cetuximab, or immunotherapy with checkpoint inhibitors (pembrolizumab or nivolumab) for PD-L1-positive tumors.

After treatment, regular follow-up visits, imaging studies, and rehabilitation for swallowing, speech, and dental health are essential. Smoking cessation support, nutritional monitoring, and dental care before radiation are important parts of the care plan.

Questions to ask your doctor

• Where in my oropharynx did the cancer start — the tonsil, base of tongue, soft palate, or elsewhere?
• Was the diagnosis confirmed as HPV-independent by p16 testing? What were the results?
• What is the tumor size and histologic grade?
• What is my pathologic stage (pT and pN)?
• Did the tumor extend into adjacent structures such as the jaw bone or deep tongue muscles?
• Were surgical margins negative? Is additional treatment needed for a close or positive margin?
• Was perineural invasion or lymphovascular invasion present?
• How many lymph nodes contained cancer, and was extranodal extension found?
• Was PD-L1 testing performed, and what was the CPS score?
• What additional treatment is recommended after surgery — radiation, chemoradiation, or systemic therapy?
• How does my prognosis compare to HPV-associated oropharyngeal cancer, and what can I do to improve my outcome?
• How will swallowing, speech, and dental health be managed during and after treatment?
• What support is available to help me stop smoking and reduce alcohol use?
• How often will I need follow-up visits and imaging?